Tenascin-X is a novel diagnostic marker of malignant mesothelioma

American Journal of Surgical Pathology

Volumn 33, Issue 11, 2009, Pages 1673-1682

  Yuan, Yuan ^a   Nymoen, Dag André ^a   Stavnes, Helene Tuft ^a   Rosnes, Anne Katrine ^a   Bjørang, Ola ^a   Wu, Chuanyue ^b   Nesland, Jahn M ^a,c   Davidson, Ben ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Adenocarcinoma; Malignant mesothelioma; Serous effusions; TNXB

Indexed keywords

MESSENGER RNA; TENASCIN;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MESOTHELIUM CELL; OVARY CARCINOMA; PERITONEUM CANCER; POLYMERASE CHAIN REACTION; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MESOTHELIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL EFFUSION, MALIGNANT; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; RNA, NEOPLASM; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 70350446760     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181b6bde3     Document Type: Article

References (20)

1. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878-882.
2. Bedrossian CWM. Malignant Effusions: a Multimodal Approach to Cytologic Diagnosis. New-York, NY: Igaku-Shoin; 1994.
3. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ''real-time'' quantitative reverse-tran-scriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia. 2003;17:2474-2486.
4. Bristow J, Carey W, Egging D, et al. Tenascin-X, collagen, elastin, and the Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2005;139C:24-30. (Pubitemid 41739244)
5. Davidson B. The biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog. 2007;13:189-227.
6. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch. 1999;435:43-49.
7. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
8. Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006; 12:5944-5950. (Pubitemid 44703753)
9. Davidson B, Baekelandt M, Shih IEM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol. 2007;35:756-760.
10. Davidson B, Skrede M, Silins I, et al. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer. 2007;110:1264-1271.
11. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary view. Cancer. 2001;93:293-308.
12. Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J Biol Chem. 2005;280:26641-26644.
13. Kleinberg L, Holth A, Fridman E, et al. The diagnostic role of claudins in serous effusions. Am J Clin Pathol. 2007;127:928-937.
14. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008; 132:397-401.
15. Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13:16-25.
16. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1-16.
17. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143-163.
18. Suster S, Moran CA. Applications and limitations of immunohis-tochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol. 2006;13:316-329.
19. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta. 2009;1793:888-892.
20. Yuan Y, Nymoen DA, Dong HP, et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol. 2009. [Epub ahead of print]